bMSAF is a prognostic predictor for advanced hepatocellular carcinoma patients treated with immune checkpoint inhibitor camrelizumab and anti‐angiogenic agent apatinib combination therapy

Detalles Bibliográficos
Autores principales: Xu, Gehan, Cui, Liang, Li, Jin, Wang, Quanren, Li, Pansong, Xia, Xuefeng, Yi, Xin, Guan, Quanlin, Xu, Jianming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574487/
https://www.ncbi.nlm.nih.gov/pubmed/36245284
http://dx.doi.org/10.1002/ctm2.1086

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574487/
https://www.ncbi.nlm.nih.gov/pubmed/36245284
http://dx.doi.org/10.1002/ctm2.1086

Ejemplares similares